MyMedR

Displaying all 2 publications

Abstract:

Sort:

Fulltext Assessment of coastal sustainable development along the maritime silk road using an integrated natural-economic-social (NES) ecosystem

Zuo J, Zhang L, Chen B, Liao J, Hashim M, Sutrisno D, et al.

Heliyon, 2023 Jun;9(6):e17440.
PMID: 37426792 DOI: 10.1016/j.heliyon.2023.e17440

Understanding spatial change and its driving factors behind coastal development is essential for coastal management and restoration. There is an urgent need for quantitative assessments of sustainable development in the coastal ecosystems that are most affected by anthropogenic activities and climate change. This study built a theme-based evaluation methodology with the Natural-Economic-Social (NES) complex ecosystem and proposed an evaluation system of coastal sustainable development (CSD) to understand the complex interactions between coastal ecosystems and anthropogenic activities. The approach revealed the levels of coastal natural, economic, and social sustainable development in the countries along the Maritime Silk Road (MSR) from 2010 to 2020. The results showed (1) a decreasing trend for coastal sustainable development between 2010 and 2015 and a rapid increasing trend between 2015 and 2020; (2) spatially varied CSD, with higher levels in Europe and Southeast Asia and lower levels in South and West Asia and North Africa; and (3) a strong influence on CSD by a combination of economic and social factors and relatively little influence by natural factors. The study further assessed the natural, economic, and social development scores for 41 countries and compared them with the mean scores (MSR) to classify coastal development patterns into three stages (favorable, transitional, and unfavorable). Finally, in the context of the 2030 Agenda for Sustainable Development, the study highlighted the importance of more refined global indicators for CSD assessments.
Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models

Arshad M, Azad A, Chan PYK, Vigneswara V, Feldinger K, Nafi SNM, et al.

Br J Cancer, 2024 Apr 10.
PMID: 38600326 DOI: 10.1038/s41416-024-02665-z

BACKGROUND: Previous studies have suggested that patients with HER2-low breast cancers do not benefit from trastuzumab treatment although the reasons remain unclear.
METHODS: We investigated the effect of trastuzumab monotherapy and its combination with different HER2 targeting treatments in a panel of breast cancer cell lines and patient-derived organoids (PDOs) using biochemical methods and cell viability assays.
RESULTS: Compared to sensitive HER2 over-expressing (IHC3 + ) breast cancer cells, increasing doses of trastuzumab could not achieve IC50 in MDA-MB-361 (IHC 2 + FISH + ) and MDA-MB-453 (IHC 2 + FISH-) cells which showed an intermediate response to trastuzumab. Trastuzumab treatment induced upregulation of HER ligand release, resulting in the activation of HER receptors in these cells, which could account for their trastuzumab insensitivity. Adding a dual ADAM10/17 inhibitor to inhibit the shedding of HER ligands in combination with trastuzumab only showed a modest decrease in the cell viability of HER2-low breast cancer cells and PDOs. However, the panHER inhibitor neratinib was an effective monotherapy in HER2-low breast cancer cells and PDOs, and showed additive effects when combined with trastuzumab.
CONCLUSION: This study demonstrates that neratinib in combination with trastuzumab may be effective in a subset of HER2-low breast cancers although further validation is required in a larger panel of PDOs and in future clinical studies.

Filters

Please provide feedback to Administrator ([email protected])

External Links